Mirum Pharmaceuticals (MIRM) Operating Leases (2019 - 2026)

Mirum Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Operating Leases rose 93.17% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (up 93.17% YoY), while the FY2025 annual figure was $7.5 million, down 5.72% from the prior year.
• Operating Leases was $13.5 million for Q1 2026 at Mirum Pharmaceuticals, up from $7.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $13.5 million in Q1 2026 to a low of $617000.0 in Q4 2023.
• Historically, Operating Leases has averaged $4.9 million across 5 years, with a median of $1.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 50.91% in 2023, then jumped 1192.06% in 2024.
• A 5-year view of Operating Leases shows it stood at $1.3 million in 2022, then tumbled by 50.91% to $617000.0 in 2023, then surged by 1192.06% to $8.0 million in 2024, then fell by 5.72% to $7.5 million in 2025, then surged by 79.99% to $13.5 million in 2026.
• The last three Operating Leases figures came in at $13.5 million (Q1 2026), $7.5 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.